comparemela.com

Latest Breaking News On - Vita salute san - Page 1 : comparemela.com

Unlocking Long-Term Success: Insights From 5-Year Follow-Up of the CAPTIVATE Trial in CLL/SLL

Paolo Ghia, MD, PhD, discusses long-term efficacy data for fixed-duration ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia.

San diegoUnited statesPaolo ghiaDivision of experimental oncologyStrategic research programSan raffaele scientific instituteExperimental oncologyB cell neoplasia unitVita salute san

Zanubrutinib Improves PFS in Treatment-Naive CLL/SLL, Regardless of Complex Karyotypes

Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.

San raffaele scientific instituteDivision of experimental oncologyStrategic research programB cell neoplasia unitVita salute sanExperimental oncologyPhase 3 sequoia trial nct03336333

Italians find one of engines behind pancreatic cancer - English

A team of Italian scientists have found one of the engines that drive cancer of the pancreas, one of the most aggressive tumours, in a discovery that has enabled them to identify a therapeutic target to hopefully slow the advance of the disease. © ANSA

Fondazione aircRenato ostuniEuropean research councilInnate immune system genomics labFrench instituteUniversity of shanghaiIstituto san raffaeleIstituto telethonFrench institute for healthMedical researchIstituto sr tigetVita salute san

vimarsana © 2020. All Rights Reserved.